Several new studies presented
Tuesday at a major Alzheimer’s conference describe progress in a series of
immune-based therapies that target the tau protein, one of the two major
proteins implicated in Alzheimer’s disease.
As a focus of research, tau protein
‘tangles’ have typically taken a backseat to another protein, the beta amyloid
plaques that proliferate in the brains of people with Alzheimer’s.
However, the new studies suggest
that not only do some tau-focused therapies show promise, some treatments
targeted against beta amyloid also affect tau.
William Thies, chief medical and
scientific officer at the Alzheimer’s Association, called the new results
“encouraging.”
Related Videos
